PatientsVille.com Logo

HYPERGLYCAEMIA and Metformin

PatientsVille

HYPERGLYCAEMIA Symptoms and Causes

Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way.

People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

Check out the latest treatments for HYPERGLYCAEMIA

HYPERGLYCAEMIA treatment research studies

Metformin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Metformin Side Effects

Lactic Acidosis (2533)
Renal Failure Acute (1526)
Diarrhoea (990)
Vomiting (735)
Blood Glucose Increased (635)
Hypotension (588)
Nausea (587)
Haemodialysis (566)
Hypoglycaemia (554)
Completed Suicide (515)
Metabolic Acidosis (488)
Abdominal Pain (385)
Dehydration (375)
Renal Failure (366)
Cardiac Arrest (346)
Dyspnoea (333)
Malaise (311)
Toxicity To Various Agents (287)
Hyperkalaemia (276)
Dizziness (259)
Overdose (258)
Renal Impairment (256)
Blood Creatinine Increased (235)
Asthenia (233)
Intentional Overdose (229)
Suicide Attempt (227)
Confusional State (213)
Fatigue (212)
Myocardial Infarction (207)
Weight Decreased (196)
Decreased Appetite (183)
Hypothermia (179)
Headache (177)
Abdominal Pain Upper (177)
Pancreatitis Acute (175)
Blood Glucose Decreased (163)
Pain (161)
Shock (159)
Continuous Haemodiafiltration (157)
Multi-organ Failure (153)
Abdominal Discomfort (153)
Somnolence (149)
Fall (149)
Agitation (148)
Diabetes Mellitus Inadequate Control (145)
Loss Of Consciousness (143)
Pancreatitis (137)
Pneumonia (126)
Poisoning (125)
Hypertension (120)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

HYPERGLYCAEMIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Pediatric Critical Illness Hyperglycemia and Glycemic Control Registry
Condition: Hypoglycemia Hyperglycemia
Intervention:
Outcome Measures: Identify and manage hyperglycemia in pediatric intensive care unit;   Consortium of centers practiced at glycemic control in pediatric intensive care unit.
2 Unknown  Metformin and Transient Hyperglycemia
Conditions: Acute Lymphoblastic Leukemia;   Hyperglycemia;   Insulin Resistance;   Diabetes Mellitus
Intervention: Drug: Metformin
Outcome Measures: Length of insulin therapy (days);   Total daily dose of insulin (unit of insulin per kilogram of subject's weight;   Number of insulin injections per day;   Serum fructosamine level;   Length of hospital stay (days);   Hemoglobin A1c
3 Unknown  Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia
Conditions: Gestational Diabetes Mellitus;   Pregestational Diabetes Mellitus;   Mild Gestational Hyperglycemia
Interventions: Other: Home care;   Other: Hospital care
Outcome Measures: Maternal mortality and morbidity rates;   Perinatal mortality and morbidity rates;   Birth weight (classified as appropriate for gestational age = AIG, small for gestational age =SGA and large for gestational age = LGA);   Maternal hospitalizations for any causes (home care) and prolonged hospitalization (hospital care);   Infants repeated hospitalizations;   Infants acute care visits;   Length of stay for delivery;   Maternal prenatal and postpartum acute care visits;   Biophysical profile tests;   Incidence of premature infants;   Postpartum repeated hospitalization;   Glucose control;   Costs
4 Unknown  Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia
Conditions: Critical Illness;   Hyperglycemia;   Mechanical Ventilation;   Enteral Nutrition;   Metabolic Stress
Interventions: Dietary Supplement: T-Diet plus Diabet IR;   Dietary Supplement: ISOSOURCE PROTEIN FIBRE;   Dietary Supplement: GLUCERNA SELECT
Outcome Measures: Measure of biochemical parameters and evaluation of infectious complications;   Assessment of critical ill patients progress during hospital stay
5 Recruiting Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy
Condition: Hyperglycemia Steroid-induced
Interventions: Drug: Sliding scale insulin;   Drug: Intermediate acting insulin;   Behavioral: Dietary advice;   Drug: Glucose lowering medication;   Drug: Chemotherapy
Outcome Measures: Glycemic control;   Patient satisfaction;   Clinical outcomes;   Hypoglycemia
6 Recruiting Green Tea Confections For Managing Postprandial Hyperglycemia-Induced Vascular Endothelial Dysfunction
Conditions: Hyperglycemia;   Cardiovascular Disease
Intervention: Dietary Supplement: Green Tea Concentrate
Outcome Measures: Postprandial Glycemia;   Vascular Function
7 Unknown  Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
Conditions: Diabetes Mellitus Type 2;   Severe Hyperglycemia - Blood Glucose Level >300mg/dl.
Interventions: Drug: Glipizide XL;   Drug: Saxagliptin + Metformin XR;   Drug: Metformin XR
Outcome Measures: The proportion of responders in each arm. Responder: FBG 70-300 and/or PPBG <400 mg/dl (week1-6), FBG 70-250 and/or PPBG <300 mg/dl (week 7-12) and without metabolic exclusion criteria, repeat ED visits, hospitalization or significant hypoglycemia.;   Proportion of patients achieving FBG goal of 70-130 mg/dl at 12 weeks in the 2 treatment arms;   Percentage of patients with symptomatic hypoglycemia;   To measure percentage compliance with medication in the two treatment arms.;   The number of fold increase in beta cell function in the 2 arms.
8 Recruiting The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Conditions: Hyperglycemia;   Diabetes Mellitus
Interventions: Drug: Active Comparator: Glargine/Lispro insulin;   Drug: Glargine/Lispro/NPH insulin arm
Outcome Measures: Average daily glucose levels in patients treated with glargine and lispro (G/L) versus glargine, lispro and NPH (G/L/N) on days 2-5 after the initiation of the treatment protocol.;   The incidence of hyperglycemia (mean daily FSG >180 mg/dL) with the two regimens.;   The incidence of hypoglycemia (FSG < 70 mg/dL) with the two regimens.
9 Recruiting Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Conditions: Acute Ischemic Stroke;   Diabetes;   Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL;   Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Outcome Measures: modified Rankin Scale Score;   Hypoglycemia
10 Not yet recruiting Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
Conditions: Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions: Drug: Sitagliptin;   Drug: Placebo
Outcome Measure: Difference in Fasting Glucose
11 Recruiting Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes
Conditions: Coronary Artery Disease;   Diabetes Mellitus Type 2
Intervention: Drug: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Outcome Measures: To determine whether hyperglycemia alters myocardial perfusion in subjects with type 2 diabetes;   To determine whether GLP-1 modulates myocardial perfusion in subjects with type 2 diabetes.
12 Recruiting Insulin by Jet-injection for Hyperglycemia in Diabetes
Condition: Diabetes Mellitus
Intervention: Drug: insulin aspart
Outcome Measures: T-BG≥10;   T-BG5 and 8 (min);   Rfall;   BG-AUC 0-2h;   BG-AUC 0-6h;   C-INSmax (pmol/l);   T-INSmax;   T-INSBL;   INSAUC;   T-INSAUC50%
13 Not yet recruiting Exenatide for Stress Hyperglycemia
Condition: Stress Hyperglycemia
Interventions: Drug: Exenatide;   Drug: Insulin
Outcome Measures: Percentage of patients spending more than 50 % of the time in the glycemic target range (100 to 140 mg/dl);   Hypoglycemia;   Severe hypoglycemia;   Number of patients needing rescue to insulin therapy protocol;   Number of adverse events occuring in the exenatide group;   Mortality;   Postoperative morbidity;   The mean (GluAve) and standard deviation (GluSD) of blood glucose;   The coefficient of variability (GluCV) of blood glucose level;   Mean number of blood glucose measured;   Mean difference between each blood glucose measurement and 120 mg/dl;   Perioperative cardiac mortality;   Perioperative non cardiac mortality;   Length of stay in intensive care unit
14 Recruiting Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery
Conditions: Type 1 Diabetes;   Type 2 Diabetes
Interventions: Drug: Regular Insulin;   Drug: Humalog
Outcome Measures: BG concentration differences at 1 and 2 hours post intervention and post operatively;   Number and percentage of target BG readings;   Episodes of hypoglycemia;   Episodes of hyperglycemia;   Total dose of insulin;   Change in glucose concentration from baseline to one, two and three hours post treatment;   Number of perioperative complications
15 Not yet recruiting Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Conditions: Cushing's Disease,;   Acromegaly
Interventions: Drug: Pasireotide s.c.;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin;   Drug: Pasireotide LAR;   Drug: Metformin
Outcome Measures: Change in HbA1c from randomization to approximately 16 weeks;   Change in HbA1c and FPG (Fasting Plasma Glucose) from randomization over time and to Core EOP (End of Phase) (only for FPG) per randomized arm;   Proportion of patients who required anti-diabetic rescue therapy with insulin in the incretin based arm;   Change in HbA1c and FPG from baseline to Core EOP;   Proportion of patients with ≤ 0.3% HbA1c increase from baseline to Core EOP per randomized arm.;   Safety and tolerability of pasireotide and anti-diabetic treatments;   Incidence of hypoglycemia events
16 Recruiting Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus
Conditions: Stress Hyperglycemia;   Diabetes Mellitus Type 2
Intervention:
Outcome Measure: Percentage of Subjects with an HbA1c greater than or equal to 6.5%
17 Recruiting Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant
Conditions: Hyperglycemia;   Malignant Neoplasm
Intervention: Other: computer-assisted intervention
Outcome Measures: Percentage of glucose values within target range (100-140) with a given CGGMS;   Percentage of patients who experience hypoglycemia (defined as at least one blood glucose value less than 70);   Percentage of patients who experience severe hypoglycemia (defined as at least one blood glucose value less than 40);   Mean time to target range (100-140);   Percentage of patients who experience hyperglycemia (defined as at least one blood glucose value greater than 200) 24 hours after initiation of infusion;   Percentage of patients who experience severe hyperglycemia (defined as at least one blood glucose value greater than 300) 24 hours after initiation of infusion;   Number of values greater than 200 or less than 70 per patient per day of treatment;   Glucose variability (defined as standard deviation of individual blood glucose values);   Nursing satisfaction evaluated by the Glucose Monitoring Tool Trial Evaluation Form
18 Recruiting Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia
Condition: Post-Transplant Glucocorticoid Induced Diabetes
Interventions: Drug: Neutral protamine hagedorn (NPH) insulin;   Drug: Regular human insulin or Insulin Aspart;   Drug: Insulin glargine
Outcome Measures: Blood glucose - inpatient;   Post prandial blood glucose - inpatient;   Length of inpatient hospital stay;   Blood glucose;   Hemoglobin A1C;   Post prandial blood glucose;   Hypoglycemic episodes;   Glycemic treatment failure;   Cardiovascular events;   Post-transplant infections or new antibiotic use;   Transplant graft failure;   New acute renal failure;   Mortality
19 Recruiting ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia
Condition: Type 2 Diabetes
Interventions: Drug: Insulin;   Drug: Metformin;   Drug: Sitagliptin
Outcome Measures: The primary outcome was the comparison of A1C change.;   Beta-cell function and insulin sensitivity and the proportion of subjects who reached the treatment target (A1C <7.0% or <6.5% at 6 months).
20 Not yet recruiting Acute Exercise and Glucotoxicity
Conditions: Type 1 Diabetes;   Type 2 Diabetes
Interventions: Behavioral: Exercise;   Procedure: Hyperglycemia
Outcome Measures: Pancreatic endocrine function;   Insulin sensitivity;   Endothelial function;   Oxidative stress